The call has ended.
Key takeaways
Remus delivered strong H1 growth led by international operations, though consolidated margins are skewed by a low-margin US distribution transaction.
| Revenue growth | Consolidated revenue grew 53% YoY to ₹614.12 Cr in H1. |
|---|---|
| Margins | Consolidated margins hit by one-time 2% margin US distribution transaction. |
| Order book | Solid pipeline; recently secured major $12M US order and Bolivia tenders. |
| Demand visibility | Strong international demand across 40+ countries; 1448 products under registration. |
| Management confidence | Highly confident, emphasizing niche products and first-to-market generic status. |
Growth
Consolidated revenue jumped 53% YoY to ₹614 Cr; standalone pharma grew 32% with 30% PAT margins.
Outlook
Targeting 25-30% B2C revenue contribution; H2 expected to outperform H1 based on order book and launches.
Risks
Low-margin US orders ($12M at 2% margin) significantly compress consolidated profitability; building B2C brands involves heavy upfront marketing costs.
Summary by ALFA Finder, written with AI assistance from the earnings call transcript the company filed, published . Open it on ALFA Filings ›
The results behind this call
Remus Pharmaceuticals H1 FY27 Results: Net Profit ₹24.7 Cr, Up 14.4% YoY
Remus Pharmaceuticals Ltd reported revenue from operations of ₹614.1 Cr (+53.4% YoY) and net profit of ₹24.7 Cr (+14.4% YoY) for H1 FY27.
- Key figure
- Net profit ₹24.7 Cr · +14.4% YoY
What management said last time
Full summary →From the call summary published .
Outlook they gave
Targeting 30% B2C revenue contribution in FY27; guiding 25-30% growth in B2B segment.
Growth they described
FY26 consolidated revenue at ₹854cr (up 38% YoY); PAT at ₹46cr (up 20% YoY).
Call details
| Company | Remus Pharmaceuticals Limited |
|---|---|
| NSE symbol | REMUS |
| ISIN | INE0O5T01011 |
| Call | Q2 FY27 earnings call |
| Date | Wednesday, 4 November 2026 |
| Time | 12:00 PM IST |
Remus Pharmaceuticals Limited: key numbers
- Share price
- ₹815.00
- Market cap
- ₹960.4 Cr
- Revenue (annual)
- ₹853.6 Cr
- Net profit (annual)
- ₹36.99 Cr
- P/E (TTM)
- 26.0×Sector 41.3×
- Promoter holding
- 70.95%
- FII holding
- 5.10%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Other calls on Wed, 4 Nov
Today's concalls →
